Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies. To accomplish this mission, we are dedicated to achieving these goals in Washington, D.C. and across the country.

Featured Blogs

Scientist writing on glass wall

R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot 

Stephen J. Ubl
As industry research and development leaders warn in a new letter to the Biden Administration, the Cancer Moonshot might have to call off its mission before it can get off the ground.

New analysis shows PBMs use fees as a profit center

Stephen J. Ubl
Pharmacy benefit managers (PBMs) demand more than double the amount of fees today than they did five years ago, according to a new report from Nephron Research.

340B program reaches $100 billion in sales, while patients are left behind

Nicole Longo
The 340B Drug Pricing Program has grown yet again, exceeding $100 billion in sales in 2022 when 340B-priced medicines are measured at wholesale acquisition cost.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.